Henry Ford's great-great grandson completes takeover of Scottish club Livingston
Calvin Ford, the great-great grandson of Ford Motor Company founder Henry Ford, has become the new chairman and majority shareholder of Scottish football club Livingston.
Livingston play in the Scottish Championship, the second tier of Scottish football.
Ford has acquired 100 per cent of former owner John McIlvogue's shares in Baycup Ltd, the group that has held a significant stake in the club since 2023.
Advertisement
'It's a humbling thing for me,' Ford told Sky Sports. 'When I was introduced to Livingston several months ago, immediately meeting people like (Livingston manager) David Martindale, you recognise the leadership and the emotion and the passion that he has, and that's contagious for me.
'I started researching Livingston football club and the history of it and it didn't take very long to know that this was something that I wanted to be a part of.'
McIlvogue said it was 'wonderful' for both Scottish football and Livingston.
Former chairman John Ward will remain with Livingston as a club director.
Ford is vice president of sales and marketing for Pentastar Aviation, a Michigan-based private aircraft management company. He is also an executive board member for CATCH Charity, serves on the board of directors for the Henry Ford Health System, and chairman for the Detroit crime commission.
Livingston finished the 2024-25 season in second place after being relegated from the Scottish Premiership the prior campaign. Ford was in attendance at Almondvale Stadium on Friday for Livingston's 2-0 win over Partick Thistle in the Premiership play-off semi-final.
Martindale's side will now take on whoever finishes 11th in the Premiership — either Dundee or Ross County — over two legs in the final for the chance to earn promotion back to the first tier.
The club won the Challenge Cup, a tournament contested by clubs from the second, third and fourth tiers of Scottish football as well as Premiership under-21 sides and teams from the regional Highland and Lowland football leagues, earlier this season.
(Alan Harvey/SNS Group via Getty Images)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Roche's Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options 1 First Phase III study in ES-SCLC first-line maintenance to demonstrate clinically meaningful improvements in both progression-free and overall survival 2,3 Data were presented in an oral session at the 2025 ASCO Annual Meeting and simultaneously published in The Lancet 1,4 Basel, 3 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq® (atezolizumab) in combination with lurbinectedin (Zepzelca®) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC), following induction therapy with carboplatin, etoposide and Tecentriq. The data showed that this combination reduced the risk of disease progression or death by 46% and the risk of death by 27%, compared to Tecentriq maintenance therapy alone. Safety was consistent with the known safety profiles of Tecentriq and lurbinectedin. These data were presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet.1,4 "Small cell lung cancer is an aggressive and devastating disease. At the time of diagnosis, the large majority of patients have already progressed to extensive-stage disease and only one out of five survive longer than two years', said Luis Paz-Ares, MD, PhD, Head of Medical Oncology at the Hospital Universitario 12 de Octubre in Madrid, Spain, and IMforte trial principal investigator. 'The IMforte results are very encouraging showing a potentially practice-changing option that could improve survival for patients with a very high unmet need.' "In the IMforte study, the Tecentriq and lurbinectedin maintenance regimen significantly extended survival for people living with extensive-stage small cell lung cancer,' said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. 'This study builds on Tecentriq's well-established safety and efficacy profile as the first immunotherapy for this cancer type and may provide another approach to help physicians and patients better manage this aggressive disease." Patients in the IMforte study first completed four cycles of Tecentriq combined with chemotherapy, over the course of approximately three months, before being randomised into maintenance treatment. From the point of randomisation, the median overall survival (OS) for the Tecentriq plus lurbinectedin regimen was 13.2 months versus 10.6 months for Tecentriq alone (stratified hazard ratio [HR] = 0.73; 95% CI: 0.57–0.95; p = 0.0174). Median progression-free survival (PFS) by independent assessment was 5.4 months versus 2.1 months, respectively (stratified HR = 0.54, 95% CI: 0.43–0.67; p < 0.0001). No new safety signals were observed.1 About the IMforte study IMforte [NCT05091567] is a Phase III, open-label, randomised trial evaluating the efficacy and safety of Tecentriq® (atezolizumab) plus lurbinectedin versus Tecentriq alone as first-line maintenance therapy for adults (≥18 years) with extensive-stage small-cell lung cancer (ES-SCLC). Patients first received induction therapy with Tecentriq, carboplatin and etoposide for four 21-day cycles. Those without disease progression were then randomised 1:1 to receive maintenance therapy with either Tecentriq plus lurbinectedin or Tecentriq alone until disease progression or unacceptable toxicity. The study enrolled 660 patients in the induction phase and randomised 483 patients in the maintenance phase. The study's primary endpoints were independent review facility (IRF)-assessed progression-free survival (PFS) and overall survival (OS) from randomisation into the maintenance phase.1,5 The trial is sponsored by Roche and co-funded by Jazz Pharmaceuticals. About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells. Tecentriq is approved for some of the most aggressive and difficult-to-treat forms of cancer. Tecentriq was the first cancer immunotherapy approved for the treatment of a certain type of early-stage (adjuvant) NSCLC, small cell lung cancer (SCLC) and hepatocellular carcinoma (HCC). Tecentriq is also approved in countries around the world, either alone or in combination with targeted therapies and/or chemotherapies, for various forms of metastatic NSCLC, certain types of metastatic urothelial cancer (mUC), PD-L1-positive metastatic triple-negative breast cancer (TNBC), BRAF V600 mutation-positive advanced melanoma and alveolar soft part sarcoma (ASPS). In addition to intravenous infusion, Tecentriq has been approved as a subcutaneous injection. About Roche in cancer immunotherapy To learn more about Roche's scientific-led approach to cancer immunotherapy, please follow this link: Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit ZEPZELCA is a trademark of Pharma Mar, S.A. used by Jazz Pharmaceuticals under license. All trademarks used or mentioned in this release are protected by law. References [1] Paz-Ares L, et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. Presented at: ASCO Annual Meeting; 2025 May 30-Jun 03; Chicago, IL, USA. Abstract #8006. [2] Belluomini L, et al. Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis. Seminars in Oncology. 2022; 49(5): 389-393. [3] Roviello G, et al. No advantage in survival with targeted therapies as maintenance in patients with limited and extensive-stage small cell lung cancer: a literature-based meta-analysis of randomized trials. Clin Lung Cancer. 2016; 17(5): 334–340. [4] Paz-Ares L, et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2025 Jun 02. [Internet; cited June 2025]. Available from: [5] A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte). [Internet; cited May 2025]. Available from: Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: Hans Trees, PhD Phone: +41 79 407 72 58 Sileia Urech Phone: +41 79 935 81 48 Nathalie Altermatt Phone: +41 79 771 05 25 Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83 Nina Mählitz Phone: +41 79 327 54 74 Kirti Pandey Phone: +49 172 6367262 Yvette Petillon Phone: +41 79 961 92 50 Dr Rebekka Schnell Phone: +41 79 205 27 03 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: Attachment 03062025_Phase III IMforte study of Tecentriq_en
Bloomberg
15 minutes ago
- Bloomberg
China PMI Hits Weakest in More Than Two Years
Good morning. A gauge of Chinese manufacturers unexpectedly tumbles. The UK and US will talk trade in Paris. And Saudi Arabia's hurdles are reshaping the Middle East's financial order. Listen to the day's top stories. China's Caixin purchasing manager's index unexpectedly fell in May to 48.3, as US tariffs took a toll on smaller exporters. The gauge indicates contraction ahead, and had been expected to improve, not worsen.
Entrepreneur
31 minutes ago
- Entrepreneur
5 Metrics Every Business Should Track to Maximise AI Investments
As the European AI landscape evolves, so too must the standards to measure success. Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur Europe, an international franchise of Entrepreneur Media. The Office of National Statistics (ONS) updates its shopping basket every year to reflect how consumers spend, adding new items like VR headsets or yoga mats as habits evolve. Businesses need to do the same with performance metrics. Artificial intelligence is now a central force in driving growth, yet many companies still measure success using outdated KPIs. With nearly half (42%) of European businesses now regularly using artificial intelligence (AI) — a 27% increase in just one year — the urgency is clear: if you don't measure what matters, you can't manage it. To truly maximise AI investments, C-suite leaders must update their own shopping baskets and rethink the benchmarks used to judge value. Here are five metrics that every business should be tracking to ensure AI success. 1. Data quality Even the most advanced AI models produce untrustworthy results if they're trained on inaccurate or irrelevant information. At best, this shortcoming is a temporary inconvenience that drains money and time. At worst, entrusting unsatisfactory data to AI systems leads to costly mistakes in user-level applications — all of which can damage an organisation's reputation and profit. With the success of AI hinging on high-quality data, it's important to perform regular data audits focused on improving accuracy. Routine reviews like this are a way to patrol data pipelines, checking that they're free of inconsistencies that could otherwise undermine AI outputs. 2. Data coverage Clean data is one priority; complete data is another. The AI models without access to every dataset are more vulnerable to blind spots, causing limitations in their ability to detect trends and identify key opportunities. For instance, insurers that automate their risk assessment processes with AI typically ingest data from operational logs, market patterns and even independent sources like weather forecasts. Accidentally neglecting just one of these could result in the misinterpretation of costly payout claims. To counter similar risks, conducting regular assessments of your data landscape to uncover overlooked data points. Eliminating visibility gaps allows businesses to paint a full picture of their digital environment, ensuring all data channels are readily available for AI usage. 3. Operational efficiency gains The clearest way to measure the success of a new initiative is to see how much time or money it saves compared to the previous approach. Put simply: a factory that installs a faster conveyor belt should see an increase in productivity. AI is no exception to that logic. From accelerating loan approvals to automating data entry, the long-term objective of AI in any industry is to reduce turnaround times and cut costs. Failure to gauge operational impact makes it difficult to justify ongoing investment. As such, it's sensible to measure process durations before and after AI integration — a benchmarking method DHL deployed to recognise that its AI-powered robots had delivered a 40% increase in sorting capacity, quantifying their investment's active contribution to business KPIs. 4. Adoption rate across teams Just because a solution successfully goes live, it doesn't mean adoption is fully guaranteed. Really, true value comes when AI is embedded into workflows across the whole company — not just the IT department. Some teams will immediately embrace the AI tools presented to them, whereas others need more support. To assess where training or change management might be necessary, it's helpful to track departmental usage data and run regular employee feedback surveys. This approach works for high-performing organisations, who are more likely to bring employees with them on their AI journey by providing extensive AI training. In this context, understanding digital behaviour is the starting point for extracting more engagement from AI. 5. Return on investment (ROI) Naturally, businesses leaders need to understand the financial return they're getting back from investment. However, the ROI generated from AI initiatives is often complex, involving both tangible and intangible benefits. Take the Berlin-based online retailer Zalando, which recently shared that it uses generative AI to produce digital imagery at a rapid rate. Not only has that directly reduced costs by 90%, but the faster turnaround in editorial campaigns also indirectly boosted the company's competitiveness in the fast fashion market. Every possible performance metric must be considered when curating a digital strategy. That's why it's important to develop a well-rounded ROI framework for AI — factoring in both the direct and indirect consequences of any planned change. Measure what matters, scale what works AI is already demonstrating its ability to reshape organisations, but the reality is that many still struggle to prove its concrete value. Without establishing the right criteria for success, businesses will lack accountability and struggle to align tech performance with financial gains. To maximise ROI on AI, you must clarify the standards that you wish your digital growth to be founded on. This will unlock the insights needed to safely course-correct, scale success, and build long-term trust in your AI strategy. As the AI landscape evolves, so too must the standards to measure success. Just like the ONS shopping basket reflects changing habits, businesses must ensure performance metrics reflect the realities of AI-driven operations. By focusing on data quality, coverage, efficiency, adoption, and ROI, leaders can ensure AI investments aren't just tracked but transformed into long-term value.
